Janux Therapeutics Inc Stock News

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights.

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to ...

Janux Therapeutics is a biopharmaceutical company developing novel immunotherapies to fight cancer, with promising drug candidates targeting PSMA and EGFR. JANX's TRACTr and TRACIr platforms engineer drug candidates that activate T cells in the tumor microenvironment, showing promising results in clinical trials. JANX007 achieved a 50% PSA reduction in 83% of mCRPC patients at 0.2mg or higher. ...

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights.

Janux Therapeutics (NASDAQ: JANX) stock price has gone vertical this year, making it one of the top-performing biotech companies in Wall Street. It jumped to a high of $61 on Monday about 975% above the lowest point in 2023, giving it a market cap of over $2.45 billion.

Generally, the idea of selling securities rankles the public's nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more important than the latter concept.

Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.

Janux Therapeutics' stock jumped this week after a report stated the company was exploring a sale. The company hasn't publicly commented on whether it's involved in acquisition discussions.